Maintenance of cortical bone in human parathyroid hormone(1-84)-treated ovariectomized rats

• Published in: Bone (New York, N.Y.) Vol. 28; no. 3; pp. 251 - 260
• Main Authors: Samnegård, E, Iwaniec, U.T, Cullen, D.M, Kimmel, D.B, Recker, R.R
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01-03-2001; Elsevier Science
• Subjects: 17β-Estradiol; Adult rats; Animals; Biological and medical sciences; Bone Marrow - drug effects; Cross-Sectional Studies; Densitometry; Estradiol - pharmacology; Etidronic Acid - analogs & derivatives; Etidronic Acid - pharmacology; Female; Femur - anatomy & histology; Femur - drug effects; Fundamental and applied biological sciences. Psychology; Histomorphometry; Humans; Ovariectomy; Parathyroid Hormone - pharmacology; Rats; Rats, Sprague-Dawley; Risedronate; Risedronic Acid; Skeleton and joints; Vertebrates: osteoarticular system, musculoskeletal system; Risedronate; 17β-Estradiol; Adult rats; Densitometry; Histomorphometry; Animal model; Rat; Estrogen; Diseases of the osteoarticular system; Diphosphonic acid derivatives; Bone disease; Bisphosphonates; Protein hormone; Osteoporosis; Risedronic acid; Intermittent; Female; Biological effect; Drug combination; Ovariectomy; Rodentia; Mechanical properties; Histology; Ovarian hormone; Parathormone; Vertebrata; Chemotherapy; Mammalia; Bone mass; Treatment; Parathyroid hormone; Sex steroid hormone; Cortical bone
• ISSN: 8756-3282; 1873-2763
• DOI: 10.1016/S8756-3282(00)00446-4

The purpose of this cross-sectional study was to evaluate the effects of human parathyroid hormone(1-84) (hPTH) followed by maintenance treatment with 17β-estradiol (E
2), risedronate (Ris), or a reduced dose of hPTH (LowPTH) on cortical bone in the ovariectomized (ovx) rat. Eight groups of ovx and one group of intact female rats (3.5 months) were left untreated for 11 weeks. For the following 12 weeks, four groups received subcutaneous injections of hPTH (75 μg/kg per day on 3 days/week) and four groups received vehicle. Treatments were then changed to E
2 (10 μg/kg per day on 2 days/week), Ris (3 μg/kg per day on 3 days/week), LowPTH (25 μg/kg per day on 3 days/week), or vehicle. Bone tissue was collected at weeks −11 (baseline), 0 (ovx effect), 12 (hPTH effect), 24, 36, and 48 (maintenance effect). Bone mineral density (BMD) and bone mineral content (BMC) of the diaphyseal femur and total cross-sectional area (Tt.Ar), marrow area (Ma.Ar), cortical area (Ct.Ar), and periosteal and endocortical bone formation of the tibia were measured. Ovariectomy resulted in lower BMD (weeks 0–48), unaffected BMC, and greater Tt.Ar (weeks 12 and 36), Ma.Ar (week 48), and Ct.Ar (weeks 0 and 12) compared with intact rats. Endocortical and periosteal bone formation were greater in the ovx than in the intact rats up to 23 weeks postovariectomy. Treatment of ovx rats with hPTH for 12 weeks resulted in greater cortical BMD, BMC, and endocortical bone formation than in intact or ovx controls. In ovx rats pretreated with hPTH and then treated with Ris for 36 weeks, BMD and BMC were greater and Ma.Ar was smaller than in ovx controls. In ovx rats pretreated with hPTH and then treated with LowPTH, BMD, BMC, Ct.Ar, and endocortical bone formation were greater and Ma.Ar was smaller than in ovx controls. Treatment of hPTH-pretreated rats with E
2 for 36 weeks did not affect cortical BMD, BMC, and Ct.Ar, although periosteal bone formation was lower in the E
2 group compared with the ovx group. Thus, in ovariectomized rats, cortical bone gained by 12 weeks of hPTH treatment was maintained for up to 36 weeks by treatment with risedronate or low-dose hPTH, but not with 17β-estradiol.